EXPOSURE-RESPONSE ANALYSES TO SUPPORT DOSE JUSTIFICATION OF DS-8201A, A HER2-TARGETING ANTIBODY-DRUG CONJUGATE, IN HER2-POSITIVE BREAST CANCER PATIENTS.
CLINICAL PHARMACOLOGY & THERAPEUTICS（2019）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要
CLINICAL PHARMACOLOGY & THERAPEUTICS（2019）